Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Scott Whyte is the chief digital officer for AeroSafe Global.

Articles

With the majority of large pharmaceutical manufacturers aiming for carbon neutrality by 2030, reusable packaging remains a largely untapped approach in achieving measurable ESG gains.

Building a Greener Supply Chain: Key Considerations for Cold Chain

Moderna has filed for emergency use authorization of its COVID-19 vaccine for use in young children six months to under six years of age.

Moderna Submits EUA of COVID-19 Vaccine for Use in Young Children

GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.

USPTO Issues Malaria Vaccine Patent to GeoVax

EMA has granted Novo Nordisk a positive scientific opinion on human insulin with more flexible storage without refrigeration.

Novo Nordisk Announces Positive Scientific Opinion from EMA on Human Insulin

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.

EIB Provides €15 million to IRBM

Meg Rivers is the former senior editor for 

Podcasts

In this episode of the Drug Solutions Podcast, Meg Rivers, senior editor, interviews Joy Aho, senior product manager at Be The Match BioTherapies, about sourcing autologous and allogeneic cell therapies.

Drug Solutions Podcast: Sourcing Autologous and Allogeneic Cell Therapies

ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.

ReiThera and Exothera Collaborate on Manufacturing Vaccines for Low and Middle-income Countries

Dupixent has been approved by the EC for children aged 6 to 11 years with severe asthma with type 2 inflammation.

EC Approves Dupixent for Treatment of Severe Asthma in Young Children

FDA has granted Priority Review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.

FDA Grants Priority Review to Intravenous Treatment of COVID-19 in Hospitalized Adults

ECDC and EMA have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines in the general population.